膝下病变治疗方式的网状Meta分析
该网状Meta分析纳入11项随机对照试验(1330例患者),比较五种治疗膝下病变的12个月结局。药物涂层球囊在主要通畅率方面显著优于普通球囊、裸金属支架和药物洗脱支架,药物洗脱支架在技术成功率和主要截肢方面可能更优。
要点
- 药物涂层球囊在主要通畅率上显著优于普通球囊、裸金属支架和药物洗脱支架。
- 药物洗脱支架在技术成功率和主要截肢方面可能优于其他治疗。
- 普通球囊和裸金属支架似乎疗效较差。
核心结论
- 药物涂层球囊在膝下病变主要通畅率方面显示出鼓舞人心的结果,可能在靶病变血运重建方面优于其他治疗。
- 药物洗脱支架可能在技术成功率和主要截肢方面优于其他治疗。
- 普通球囊和裸金属支架似乎是效果较差的治疗选择。
研究设计与样本
- 研究设计为随机对照试验的网状Meta分析。
- 共纳入11项研究(22个研究臂;1330例患者)。
- 比较五种治疗膝下病变的12个月主要通畅率、靶病变血运重建、主要截肢和技术成功率。
主要发现
- 药物涂层球囊相比普通球囊显著提高主要通畅率(OR 9.02,95%CI 3.18-25.55)。
- 药物涂层球囊相比裸金属支架显著提高主要通畅率(OR 14.39,95%CI 4.33-47.87)。
- 药物涂层球囊相比药物洗脱支架显著提高主要通畅率(OR 3.70,95%CI 1.20-11.11)。
- 药物洗脱支架相比普通球囊显著提高主要通畅率(OR 2.42,95%CI 1.57-3.74)。
- 药物洗脱支架相比裸金属支架显著提高主要通畅率(OR 3.86,95%CI 2.24-6.65)。
关键数值与推荐
- 药物洗脱支架相比普通球囊显著提高技术成功率(OR 11.78,95%CI 1.42-97.59)。
- 根据SUCRA值,药物涂层球囊在主要通畅率(SUCRA=99.7)和靶病变血运重建(SUCRA=70.7)方面被认为是最佳治疗。
- 根据SUCRA值,药物洗脱支架在技术成功率(SUCRA=90.6)和主要截肢(SUCRA=85.9)方面被认为是最佳治疗。
临床怎么用
- 对于膝下病变的严重肢体缺血患者,药物涂层球囊可作为改善主要通畅率的优选方案。
- 当优先考虑技术成功率和降低主要截肢风险时,药物洗脱支架可能更有利。
- 普通球囊和裸金属支架的疗效相对较差,选择时应权衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to conduct a network meta-analysis of randomized controlled trials comparing treatment modalities for infrapopliteal lesions in critical limb ischemia. METHODS: Five treatments for infrapopliteal lesions in critical limb ischemia were recognized. We compared primary patency, target lesion revascularization (TLR), major amputation at the 12-month follow-up, and technical success rate of the treatment modalities. RESULTS: Altogether, 11 studies (22 study arms; 1,330 patients) were considered eligible. The drug-eluting balloon (DEB) significantly increased primary patency compared with balloon angioplasty (BA; odds ratio [OR] 9.02, 95% confidence interval [CI] 3.18-25.55), the bare metal stent (BMS; OR 14.39, 95% CI 4.33-47.87), and the drug-eluting stent (DES; OR 3.70, 95% CI 1.20-11.11). The DES significantly increased primary patency compared with BA (OR 2.42, 95% CI 1.57-3.74) and BMS (OR 3.86, 95% CI 2.24-6.65). DES significantly increased the technical success rate compared with BA (OR 11.78, 95% CI 1.42-97.59). According to the value of the surface under the cumulative ranking curve (SUCRA), DEB was considered the best treatment in terms of primary patency (SUCRA = 99.7) and TLR (SUCRA = 70.7), and DES was considered the best treatment in terms of technical success rate (SUCRA = 90.6) and major amputation (SUCRA = 85.9). CONCLUSIONS: DEB has shown encouraging results in terms of primary patency for infrapopliteal lesions in critical limb ischemia; furthermore, DEB may be better than other treatments in terms of TLR. DES may be better than other treatments in terms of technical success and major amputation. In contrast, BA and BMS seem to be less effective treatment options.
引用
- Zhou Y, Lin S, Zhang Z, et al. A Network Meta-analysis of Randomized Controlled Trials Comparing Treatment Modalities for Infrapopliteal Lesions in Critical Limb Ischemia. Ann Vasc Surg. 2019. PMID: 31075473. doi:10.1016/j.avsg.2019.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。